@IamEmchee

GI oncologist and health services researcher at Oregon Health & Science University

 Portland, OR
Joined December 2014
  • Tweets23
  • Following97
  • Followers119
Emerson Chen retweeted
Axel Grothey@agrothey11 Sep 2020
Pembro in “TMB high” (10+) cancers - paper published in Lancet Oncol. No difference in OS between TMB high and TMB low. Neverthelessless FDA approved. SMH. @OncoAlert
10
75
6
210
Emerson Chen retweeted
Bernie Marini@Berninini30 May 2020
Friendly reminder that surrogate endpoints like PFS only reduce study time by an average of 11 months - @IamEmchee, et al. 🙂 We shouldn’t proclaim new therapies as “new standard of care”, without showing OS or QOL benefit for patients. #ASCO2020 #asco20 jamanetwork.com/journals/jam…

Study Time Estimates Using Surrogate End Points vs Overall Survival in Oncology Clinical Trials

This study analyzes the original and updated clinical trials that led to FDA-approved drug indications in oncology from 2006 to 2017 to assess reduction in clinical trial duration derived from using...

jamanetwork.com
8
1
25
Critical Care and the COVID-19 Outbreak in Italy: Early Experience and Forecast ja.ma/2wTgyUH
Dr. Christopher Booth reminds us about endpoints that matter to patients. #GI20
3
33
5
105
Canada's Transparency With Clinical Trial Puts Pressure On U.S. FDA To Reveal More : Shots - Health News : NPR npr.org/sections/health-shot…

Canada's Decision To Make Public More Clinical Trial Data Puts Pressure On FDA

The U.S. Food and Drug Administration treats most data it gets on the development of new drugs and medical devices as confidential to companies. Critics say making the data public would help patients.

npr.org
1
Couldn’t agree more, would like to tell my patients how a new therapy will directly help them. “Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs” ja.ma/2nolHiy
1
Wow amazing online course that changed how I think about oncology drugs, and completed just in time before my first day as faculty tomorrow @edxonline #mooc edx.org/course/the-fda-and-p…
2
I look forward to a response and hope Dr. @ScottGottliebMD will rectify his mistake & resign from his position at @Pfizer. It would send a strong message about the importance of integrity of current & former federal officials.
85
189
26
999
Health policy conundrum, 1) gets cancer drug approved faster but more uncertainty 2) might not get drug approved but more certainty of clinical benefit jamanetwork.com/journals/jam…

Study Time Estimates Using Surrogate End Points vs Overall Survival in Oncology Clinical Trials

This study analyzes the original and updated clinical trials that led to FDA-approved drug indications in oncology from 2006 to 2017 to assess reduction in clinical trial duration derived from using...

jamanetwork.com
Shaalan Beg MD MBA FASCO@ShaalanBeg24 Jun 2019
Replying to @GIcancerDoc @pashtoonkasi @aakonc @UqbaKhan @kmody29 @DrR_DUNNE @gabe_a_brooks @agrothey @utswcancer @ASCOPost
great point.. raises the question, should one design a trial aimed at the 1) end point you can achieve or 2) the end point which is more meaningful?
1
2
I find the sicker treatment-refractory patient tend to be on left and the healthier adjuvant/first-line metastatic patient on the right.
Michael Fisch MD MPH@fischmd4 Jun 2019
Replying to @barttels2 @oncology_bg @ASCO @ecancer @scottrberry @cpgYALE @yzafar @MartinStockler @Prof_IanD @NicoleKuderer @JackWestMD
The bargain of accelerated approvals and the spectrum of patient viewpoints on this issue was described brilliantly by @VPrasadMDMPH at #ASCO19
2
Len Saltz @sloan_kettering listing no-value interventions in #colorectalcancer Anything to add or subtract? #ASCO19 #crcsm – at Chicago, IL
6
18
1
33
On interpreting #clinicaltrials: When you hear “A HR of __ & a __month diff in PFS,” consider what the control arm is. The interpretation of those #s differs if comparator is placebo/BSC or active control, & if active control, if new drug is an add on or replacement tx. #ASCO19 – at Chicago, IL
1
12
36
Emerson Chen retweeted
Sam Sater, MD@HSaterMD2 Jun 2019
ANNOUNCE failed to meet OS primary endpoint and Olaratumab will be withdrawn after previous initial FDA @US_FDA approval. #ASCO19 #ASCO2019 #sarcoma #pdgfra – at Chicago, IL
17
3
21
In light of today’s #ASCO19 plenary, please read our latest @JAMAInternalMed paper on accelerated approval to understand this pathway’s trade offs. We even managed to sneak in a sentence about #olaratumab at the very last moment. jamanetwork.com/journals/jam… #ASCOplenary #sarcoma
4
6
“Clinical trials are there to serve patients, not the other way around.” —@oncology_bg #ASCO19 #bcsm #lcsm #crcsm #mmsm
4
33
6
77
And here’s the story covered by @rrichardh in the NPR : npr.org/sections/health-shot…
1
1
8
The biggest honor, however, is to have 2 editorials accompany our paper. I always lamented @RichardLehman1 ‘s retiring from BMJ blogs without getting chance to read his comment on my work. But now he has written an editorial instead with @cpgYALE . jamanetwork.com/journals/jam… 🙏
2
5
14
Another brilliant editorial is from Zeke Emmanuel et al. You’ll enjoy every word of this. jamanetwork.com/journals/jam…
1
4
1
8
Published just now in @JAMAInternalMed . Our assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. jamanetwork.com/journals/jam… @SpencerPHey @akesselheim @PORTAL_Research @BrighamResearch @QueensUHealth
4
37
9
68
Aspired to be a plain “trialist” but ended up looking at 170+ cancer drug registration trials since 2006: “Study Time Estimates Using Surrogate End Points vs Overall Survival in Oncology Clinical Trials” ja.ma/2K3bP8L
2
5
3
21
Load more